A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non–Small Cell Lung Cancer

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer

(2016) M. Chatterjee et al.   ANNALS OF ONCOLOGY

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Overspending driven by oversized single dose vials of cancer drugs

(2016) Peter B Bach et al.   BMJ-British Medical Journal

Overspending driven by oversized single dose vials of cancer drugs

(2016) Peter B Bach et al.   BMJ-British Medical Journal

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

(2015) A. Patnaik et al.   CLINICAL CANCER RESEARCH

Receipt of Chemotherapy Among Medicare Patients With Cancer by Type of Supplemental Insurance

(2015) Joan L. Warren et al.   JOURNAL OF CLINICAL ONCOLOGY

Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

(2015) Gregory A. Masters et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

(2015) Antoni Ribas et al.   LANCET ONCOLOGY

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Necitumumab in Metastatic Squamous Cell Lung Cancer

(2015) Daniel A. Goldstein et al.   JAMA Oncology

Indication-Specific Pricing for Cancer Drugs

(2014) Peter B. Bach   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

(2014) Caroline Robert et al.   LANCET

ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer

(2013) J. F. Gainor et al.   CLINICAL CANCER RESEARCH

Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force

(2013) Sean D. Sullivan et al.   VALUE IN HEALTH

Referral and Treatment Patterns Among Patients With Stages III and IV Non–Small-Cell Lung Cancer

(2013) Bernardo H.L. Goulart et al.   Journal of Oncology Practice

Approval Summary: Pemetrexed in the Initial Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer

(2009) M. H. Cohen et al.   ONCOLOGIST